PHILADELPHIA, July 6, 2015: Morgan Lewis is pleased to announce that its Life Sciences Industry Group continues to place among the top for licensing activities as demonstrated in the recently published quarterly rankings by BioPharm Insight’s league tables. Morgan Lewis again placed first overall for value in Europe licensing agreements for the last 12 months.
BioPharm Insight is a market provider of up-to-date information and coverage of global drug licensing deals as they take place. It publishes quarterly league tables to rank licensing activity in the life sciences industry, based on pharmaceutical drug licensing agreements announced during the period. In the latest tables, Morgan Lewis received the following rankings:
2015 First Quarter Only
- 6th - Global League Tables of Legal Advisors to Biotech and Pharma Licensing Agreements – Based on Value – ($450M)
- 7th - Global League Tables of Legal Advisors to Biotech and Pharma Licensing Agreements – Based on Volume – (3 deals)
Last 12 Months
- 1st – Europe: Legal Advisors to Biotech and Pharma Licensing Agreements – Based upon Value – ($5,918M)
- 2nd – Europe: Legal Advisors to Biotech and Pharma Licensing Agreements – Based upon Volume – (12 deals)
- 2nd – Global: Legal Advisers to Biotech and Pharma Licensing Agreements – Based upon Value – ($6,368M)
- 3rd – Global: Legal Advisers to Biotech and Pharma Licensing Agreements – Based upon Volume – (19 deals)
- 3rd – North America: Legal Advisors to Biotech and Pharma Licensing Agreements – Based upon Value – ($6,313M)
- 4th – North America: Legal Advisors to Biotech and Pharma Licensing Agreements – Based upon Volume – (17 deals)
- 10th – Asia-Pacific: Legal Advisors to Biotech and Pharma Licensing Agreements – Based upon Value
- 5th – Asia-Pacific: Legal Advisors to Biotech and Pharma Licensing Agreements – Based upon Volume – (5 deals)